Abstract 7625: The liquid biomarker thymidine kinase activity reflecting proliferation rate can provide guidance in drug development and address Project Optimus
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-7625
Abstract: Thymidine Kinase (TK) plays a basic role in DNA synthesis and cell proliferation. The enzyme is highly cell cycle dependent and correlates with cell growth state. Numerous studies have consistently shown elevated TK activity (TKa)… read more here.
Keywords: tka; drug; proliferation; tka levels ... See more keywords
Abstract PO5-18-11: Use of DiviTum®TKa as a biomarker assay for CDK4/6 inhibitor medication compliance and drug-drug interaction assessment in ER/PR positive metastatic breast cancer
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs23-po5-18-11
Abstract: Background: CDK4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) is standard first line (1L) treatment for metastatic hormone positive (ER/PR+) HER2- negative breast cancer (mBC). Some patients have progression free survival (PFS) of 2 years or… read more here.
Keywords: cancer; cdk4; tka; drug ... See more keywords
Abstract P2-05-16: Interrogating serum thymidine kinase activity with CDK4/6 inhibitor-based therapies: real-world experience in the metastatic and adjuvant setting
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-p2-05-16
Abstract: Background: CDK4/6 inhibitors have become widely deployed in the treatment of HR+/HER2- breast cancer. In the metastatic setting, a number of different CDK4/6 inhibitors are approved in combination with endocrine therapy and lead to a… read more here.
Keywords: tka levels; inhibitor based; cdk4 inhibitor; cdk4 ... See more keywords